1. Efficacy of the sibutramine in the insulin resistance and glycaemic control of obese patients / Eficacia de la sibutramina en la resistencia insulínica y el control glucémico de pacientes obesos
- Author
-
Pereira LRL, Queiroz RHC, Bianchi MLP, and Junior NL
- Subjects
lcsh:Pharmacy and materia medica ,DOAJ:Pharmacy and materia medica ,DOAJ:Medicine (General) ,endocrine system diseases ,Glycaemic control ,lcsh:R ,Sibutramine ,lcsh:RS1-441 ,lcsh:Medicine ,Insulin resistance ,Obesity ,DOAJ:Health Sciences ,Metformin - Abstract
Objective: This paper compared the effects of the sibutramine and of the metformin in the patients' obesity bearers insulin resistance. Methods: They were appraised 16 subjects obese with IMC above 30 Kg/m2, during 6 months and divided in two groups. The patients, before they begin the study, they were submitted to an evaluation anthropometric, clinic and laboratorial. All the patients received an individualized alimentary plan, respecting the total energy expense daily. Results: At the end of the study, it was observed that the plasmatic concentrations of insulin suffered reduction of 12,1% (sibutramine) and 20,7% (metformin), and the values of HOMA also suffered reduction of 11,2% and 23,5%, respectively in the group sibutramine and metformin. In compensation, the patients of the group sibutramine obtained more satisfactory results than the group metformin in the reduction of the corporal weight and in IMC.Conclusion: This study demonstrated that the sibutramine, when compared to the metformin, it presents good results in the patients' glycaemic control, mainly in the insulin values and HOMA. The sibutramine, when prescribed in a rational way, an important therapeutic tool can be considered in the control of the diabetes type 2 and others adjunct pathology, however it should always be used simultaneous with an agent antidiabetic in those patient ones.
- Published
- 2005